Covid-19 Vaccine Effectiveness in New York State

The effectiveness of the BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines was assessed from May through August 2021. Initial protection was high, but there was a modest waning after the delta variant surged and public health mitigation policies changed. Protection against hospitalization remained high

Candida auris in Healthcare Facilities, New York, USA, 2013–2017

Candida auris is an emerging yeast that causes healthcare-associated infections. It can be misidentified by laboratories and often is resistant to antifungal medications. We describe an outbreak of C. auris infections in healthcare facilities in New York City, New York, USA. The investigation included laboratory surveillance, record reviews, site visits, contact tracing with cultures, and environmental sampling. We identified 51 clinical case-patients and 61 screening case-patients. Epidemiologic links indicated a large, interconnected web of affected healthcare facilities throughout New York City. Of the 51 clinical case-patients, 23 (45%) died within 90 days and isolates were resistant to fluconazole for 50 (98%). Of screening cultures performed for 572 persons (1,136 total cultures), results were C. auris positive for 61 (11%) persons. Environmental cultures were positive for samples from 15 of 20 facilities. Colonization was frequently identified during contact investigations; environmental contamination was also common

Receptor for advanced glycation end products (RAGE) protein expression in lung tissue from individual RAGE(lanes 1 to 3), RAGE(lanes 4 to 6), and RAGE(lanes 7 to 9) animals

<p><b>Copyright information:</b></p><p>Taken from "Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection"</p><p>http://ccforum.com/content/11/6/R122</p><p>Critical Care 2007;11(6):R122-R122.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2246216.</p><p></p> Actin was used to demonstrate equal loading

Lethality from cecal ligation and puncture (CLP) is decreased in BALB/c mice administered an anti-RAGE monoclonal antibody (mAb)

<p><b>Copyright information:</b></p><p>Taken from "Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection"</p><p>http://ccforum.com/content/11/6/R122</p><p>Critical Care 2007;11(6):R122-R122.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2246216.</p><p></p> The Kaplan-Meier survival analysis following CLP compares anti-RAGE mAb-treated animals given 7.5 mg/kg (= 15) or 15 mg/kg (= 15) intravenously 30 to 60 minutes before CLP with serum control animals (= 15). The group given 15 mg/kg had a significantly greater survival than the group given 7.5 mg/kg (< 0.05) or serum control (< 0.001). RAGE, receptor for advanced glycation end products

Delayed administration of the anti-RAGE antibody is protective in cecal ligation and puncture (CLP)

<p><b>Copyright information:</b></p><p>Taken from "Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection"</p><p>http://ccforum.com/content/11/6/R122</p><p>Critical Care 2007;11(6):R122-R122.</p><p>Published online 6 Nov 2007</p><p>PMCID:PMC2246216.</p><p></p> The Kaplan-Meier survival analysis following CLP in BALB/c mice compares delayed anti-RAGE monoclonal antibody (mAb) treatment given at various time intervals after CLP with serum control. Each group had a significantly greater survival than the control group (< 0.01), except for the 36-hour delayed treatment group (= 0.12). RAGE, receptor for advanced glycation end products